← Back to Search

Alpha-2 Adrenergic Agonist

Early tramal/bupivacaine for Pain relief

Phase 2 & 3
Waitlist Available
Led By Ehab H Gendy, MD
Research Sponsored by National Cancer Institute, Egypt
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Summary

Multiple modalities for postoperative analgesia after laparoscopic procedures has been used, of them intraperitoneal route (IP) was used to decrease the analgesic requirements. Both early and late bupivacaine and tramadol versus bupivacaine and dexmedetomedine will be tried to choose which is having a better analgesic profile.

Eligible Conditions
  • Pain relief

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The degree of pain

Trial Design

4Treatment groups
Active Control
Group I: Early tramal/bupivacaineActive Control3 Interventions
patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of the first two trocars before starting the surgery.
Group II: Late tramal/bupivacaineActive Control3 Interventions
patients received 50ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
Group III: Early dexmedetomedine/bupivacaineActive Control3 Interventions
patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% before creation of a pneumoperitoneum and placement of the first two trocars before the start of surgery.
Group IV: Late dexmedetomedine/bupivacaineActive Control3 Interventions
patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.

Find a Location

Who is running the clinical trial?

National Cancer Institute, EgyptLead Sponsor
108 Previous Clinical Trials
8,287 Total Patients Enrolled
Ehab H Gendy, MDPrincipal InvestigatorAssistant Professor of Anesthesia, intensive care and pain releif
2 Previous Clinical Trials
150 Total Patients Enrolled
~22 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top